Evidence of polyclonal hematopoiesis in a large proportion of patients with low-risk myelodysplastic syndrome.

被引：0
作者：
Malcovati, L
Della Porta, MG
Galli, A
Boggi, S
Malabarba, L
Pietra, D
Passamonti, F
Bergamaschi, G
Lazzarino, M
Cazzola, M
机构：
[1] Univ Pavia, Div Hematol, Sch Med, I-27100 Pavia, Italy
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2364
引用
收藏
页码：649A / 650A
页数：2
相关论文
共 50 条
  • [21] MULTICENTER COMPARISON OF CD34+MYELOID CELL COUNT BY FLOW CYTOMETRY IN LOW-RISK MYELODYSPLASTIC SYNDROME. IS IT FEASIBLE?
    Font, P.
    Subira, D.
    Matarraz, S.
    Benavente, C.
    Cedena, T.
    Morado, M.
    Perez-Corral, A.
    Bellon, J. M.
    Diez-Martin, J. L.
    LEUKEMIA RESEARCH, 2017, 55 : S98 - S99
  • [22] SWITCHING TO AN ALTERNATIVE RECOMBINANT ERYTHROPOIETIN AGENT MAY BE EFFECTIVE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME
    Fattizzo, B.
    Rizzo, L.
    Giannotta, J. A.
    Cecchi, N.
    Mazzon, F.
    Barcellini, W.
    Riva, M.
    HAEMATOLOGICA, 2021, 106 (10) : 173 - 173
  • [23] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [24] RECOVERY OF POLYCLONAL HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FOLLOWING SUCCESSFUL CHEMOTHERAPY
    ITO, T
    OHASHI, H
    KAGAMI, Y
    ICHIKAWA, A
    SAITO, H
    HOTTA, T
    LEUKEMIA, 1994, 8 (05) : 839 - 843
  • [25] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
  • [26] Utilization Patterns and Outcomes from Iron Chelation in Elderly Patients with Low-Risk Myelodysplastic Syndrome
    Herrera, Diego Adrianzen
    Sparks, Andrew
    Singh, Rohit
    Giorgio, Katherine
    Lutsey, Pamela
    Zakai, Neil
    BLOOD, 2023, 142
  • [27] Treatment of low-risk myelodysplastic syndromes
    Santini, Valeria
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
  • [28] Ineffective hematopoiesis linked with a mitochondrial tRNA mutation in a patient with myelodysplastic syndrome.
    Gattermann, N
    Wulfert, M
    Junge, B
    Germing, U
    Haas, R
    Hofhaus, G
    BLOOD, 2003, 102 (11) : 326B - 327B
  • [29] Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
    Vicente, Alana
    Patel, Bhavisha A.
    Gutierrez-Rodrigues, Fernanda
    Groarke, Emma M.
    Giudice, Valentina
    Lotter, Jennifer
    Feng, Xingmin
    Kajigaya, Sachiko
    Weinstein, Barbara
    Barranta, Evette
    Olnes, Matthew J.
    Parikh, Ankur R.
    Albitar, Maher
    Wu, Colin O.
    Shalhoub, Ruba
    Calvo, Katherine R.
    Townsley, Danielle M.
    Scheinberg, Phillip
    Dunbar, Cynthia E.
    Young, Neal S.
    Winkler, Thomas
    HAEMATOLOGICA, 2020, 105 (12) : 2785 - 2794
  • [30] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
12345